A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC)

被引：35

作者：

Faivre, Sandrine J.

Santoro, Armando

Kelley, Robin Kate

Merle, Philippe

Gane, Ed

Douillard, Jean-Yves

Waldschmidt, Dirk

Mulcahy, Mary Frances

Costentin, Charlotte

Minguez, Beatriz

Papappicco, Pasqua

Gueorguieva, Ivelina

Cleverly, Ann

Desaiah, Durisala

Lahn, Michael M.

Ameryckx, Sophie

Benhadji, Karim A.

Raymond, Eric

Giannelli, Gianluigi

机构：

[1] Hop Beaujon, Clichy, France

[2] Ist Clin Humanitas, Milan, Italy

[3] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[4] Hop De La Croix Rousse, Lyon, France

[5] Auckland City Hosp, Auckland, New Zealand

[6] Ctr Rene Gauducheau, F-44035 Nantes, France

[7] Univ Klinikum Koln, Cologne, Germany

[8] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[9] Hosp Henri Mendor, Creteil, France

[10] Vall dHebron Hosp, Liver Unit, Barcelona, Spain

[11] Univ Bari, Sch Med, Bari, Italy

[12] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.3_suppl.lba173

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

LBA173

引用

页数：1